Shire   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Hampshire United Kingdom (1986)
Status: Acquired by Takeda (2018)

Organization Overview

First Clinical Trial
1995
NCT00172107
First Marketed Drug
1986
nitrofural
First NDA Approval
1990
moricizine (ethmozine)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Baxalta Innovations GmbH, now part of Shire | Baxalta now part of Shire | Baxalta US Inc., now part of Shire | Shire | SHIRE | Shire (Baxalta) | SHIRE DEV LLC | SHIRE HUMAN GENETIC | Shire Human Genetic Therapies, Inc. | Shire Inc, | Shire Inc. | Shire International GmbH | SHIRE LLC | SHIRE ORPHAN THERAP | Shire Orphan Therapies, LLC | SHIRE RICHWOOD